In-situ Hybridization Market Size, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027
Report ID: GMI3991
In-situ Hybridization Market size is projected to experience significant growth from 2019 to 2025.
Growing prevalence of cancer and congenital abnormalities will stimulate the growth of global in-situ hybridization business over the coming years. The growing adoption of in-situ hybridization technique to detect cytogenetic disorders will further upsurge the market growth. According to the National Cancer Institute, nearly 1.7 million people are diagnosed with cancer in the United States every year. Thus, the rising prevalence of cancer necessitates clinical research, thereby boosting the growth of in-situ hybridization technique.
Growing demand for more precise diagnosis and government initiatives to spread awareness regarding the widespread use of new tools and technologies will further assist the industry growth. Furthermore, increase in research and development activities coupled with technological breakthroughs will significantly impact the industry growth.
Recent modifications in the in-situ hybridization technique such as strand displacement amplification and molecular beacons permits multi-target visualization and quantitative analysis. Additionally, growing application of in-situ hybridization technique in pharmaceutical and biotechnology companies for early drug discovery will further assist in-situ hybridization market growth over the forthcoming years.
However, the availability of better techniques such as high-throughput whole genome sequencing and microarray confines the industry growth. Stringent regulatory policies and less tissue penetration of some probes used in in-situ hybridization will hinder the use of this technique in few regions.
RNA probes segment will dominate the market over the forecast years. The growth will be attributed to the sensitivity and specificity of RNA probes for detecting cancer. Advantages associated with the use of RNA probes such as stability and low cost will increase their demand over the forthcoming years. Additionally, RNA probes are thermodynamically stable than DNA probes that makes the labelling reaction more effective.
Fluorescence in-situ hybridization (FISH) technique segment will grow at a significant pace over the projected timeframe owing to high sensitivity, specificity and speed of technique. Rising adoption of fluorescence in-situ hybridization technique for diagnosis of congenital diseases will supplement segmental growth. According to National Down Syndrome Society, nearly 6000 babies are born with down syndrome in the U.S. annually. FISH is currently being used to detect chromosomal abnormalities associated with cancer due to its high sensitivity. FISH is 50 times more sensitive than routine cytology test. Thus, rising prevalence of cancer will spur the demand for accurate diagnostic tests, thereby boosting the overall segmental growth over the forthcoming years.
Use of in-situ hybridization in cancer diagnosis will grow at a significant pace due to high prevalence of cancer and high specificity and sensitivity of ISH. Fluorescence in-situ hybridization technique is commonly used for diagnosis of cancer as it is 50 times more sensitive than routine cytology test. Additionally, growing adoption and approval of FISH probes for diagnosis of breast and lung cancer in developed as well as developing countries will boost the industry growth.
Research and diagnostic laboratories will dominate the end-use segment due to increased use of in-situ hybridization method for research and diagnostic purpose. ISH is preferred over routine cancer diagnostic tests due to its sensitivity. Rise in number of cancer and genetic disorders will spur the demand for accurate and sensitive diagnostic testing, thereby fueling the in-situ hybridization market. The pharmaceutical and biotechnology companies segment is anticipated to grow over the coming years owing to the application of in-situ hybridization technique in new drug development.
The U.S. in-situ hybridization market is anticipated to witness significant growth owing to presence of well-established diagnostic laboratories coupled with high prevalence of cancer and genetic disorders in the country. The American Society of Clinical Oncology/College of American Pathologists recommends the use of fluorescence in-situ hybridization method for diagnosis of breast cancer. With rising prevalence of breast cancer, the adoption of FISH for diagnosis will increase, fueling the industry growth. Additionally, high investment in research activities and rise in biomedical research will further pose lucrative business growth opportunity over the forecast period.
China in-situ hybridization market is expected to grow at a significant pace due to increased incidence of cancer. According to the European Society for Medical Oncology, cancer is leading cause of death in China with more than 2.8 million cancer deaths in 2015. Increasing healthcare expenditure and healthcare infrastructure development will further fuel the market growth. Additionally, FISH is adopted and approved by China Food and Drug Administration for breast cancer detection. However, high cost of FISH will pose negative impact on industry growth.
Some of the major market players involved in the global in-situ hybridization market are PerkinElmer, Thermo Fisher Scientific, BioGenex, Genemed Biotechnologies, Biocare Medical, among others. Companies are implementing competitive strategies such as acquisitions and new product development to broaden their product portfolio and expansion of market share. For instance, in 2015, Biocare Medical, LLC. acquired Cymogen DX. The acquisition added FISH probes of Cymogen DX to the diagnostic product portfolio of Biocare Medical, LLC.
In-situ Hybridization Market, by Probe Type, 2014-2025 (USD Million)
- Double-stranded DNA (dsDNA) probes
- Single-stranded DNA (ssDNA) probes
- Synthetic oligonucleotides (PNA, LNA)
In-situ Hybridization Market, by Technique, 2014-2025 (USD Million)
- Chromogenic in-situ hybridization
- Fluorescence in-situ hybridization
- Cas9-mediated fluorescence in-situ hybridization
In-situ Hybridization Market, by Application, 2014-2025 (USD Million)
- Cancer diagnosis
- Karyotyping and phylogenetic analysis
- Physical mapping
- Developmental biology
In-situ Hybridization Market, by End-use, 2014-2025 (USD Million)
- Research & diagnostic laboratories
- Academic institutes
- Pharmaceutical and biotechnology companies
- Contract research organizations (CROs)
The above information is provided for the following regions and countries:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- South Africa
- Saudi Arabia
- PerkinElmer, Inc.
- Thermo Fisher Scientific, Inc.
- Accelerate Diagnostics, Inc.
- F. Hoffmann-La Roche AG
- Leica Biosystems Nussloch GmbH
- Agilent Technologies
- Advanced Cell Diagnostics, Inc.
- Bio SB
- Abnova Corporation
- Biosearch Technologies Inc.
- Genemed Biotechnologies, Inc.
- Biocare Medical, LLC.
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability
Benefits of Association
Data Coverage & Quality
GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.
Client Trust & Security
GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.
Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.